Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics (NASDAQ:CRDL) will participate in a Fireside Chat at the H.C.
Rhea-AI Summary
Cardiol Therapeutics (NASDAQ:CRDL) will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ in New York.
The session is scheduled for May 19, 2026 at 1:30 p.m. EDT, with a live webcast and a replay available for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRDL
In the May 14 session, CRDL gained 0.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference
- Presentation time
- 1:30 p.m. EDT
- Scheduled Fireside Chat session at the conference
- Replay availability
- 90 days
- Webcast replay duration after the conference
Historical Context
-
Phase II MAvERIC results accepted in a major cardiology journal.
-
U.S. MAVERIC Phase III network expanded with additional clinical centers.
-
Live interview highlighting MAVERIC Phase III and ARCHER Phase II data.
-
Year-end 2025 update on trials, IP, financing, and pipeline progress.
-
Announcement of TD Cowen healthcare conference presentation and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). The replay will be available for 90 days following the conference.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The
The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.
The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-hc-wainwright-4th-annual-bioconnect-investor-conference-at-the-nasdaq-302772040.html
SOURCE Cardiol Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.